Sunshine Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
SBFM$2.75+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Page | |
|---|---|
| Defined Terms | i |
| Forward Looking Statements | ii |
| PART I | 1 |
| Item 1. Business | 1 |
| Item 1A. Risk Factors | 7 |
| Item 1B. Unresolved Staff Comments | 17 |
| Item 1C. Cybersecurity | 17 |
| Item 2. Properties | 17 |
| Item 3. Legal Proceedings | 17 |
| Item 4. Mine Safety Disclosures | 17 |
| PART II | 18 |
| Item 5. Market for the Registrant’s Common Equity Related Stockholder Matters and Issuer Purchases of Equity Securities | 18 |
| Item 6. Reserved. | 18 |
| Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 18 |
| Item 7A. Quantitative and Qualitative Disclosures About Market Risk | 21 |
| Item 8. Financial Statements and Supplementary Data | 22 |
| Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 41 |
| Item 9A. Controls and Procedures | 41 |
| Item 9B. Other Information | 41 |
| Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. | 41 |
| PART III | 42 |
| Item 10. Directors, Executive Officers and Corporate Governance | 42 |
| Item 11. Executive Compensation | 45 |
| Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 46 |
| Item 13. Certain Relationships and Related Transactions, and Director Independence | 48 |
| Item 14. Principal Accounting Fees and Services | 48 |
| PART IV | 49 |
| Item 15. Exhibits, Financial Statement Schedules | 50 |
| Signatures | 51 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.